Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Higher BPA exposure tracked with higher estrogen and progesterone in women

24

Aug 2026

Higher BPA exposure tracked with higher estrogen and progesterone in women

Researchers found that higher urinary concentrations of BPA and several phthalate metabolites were associated with higher serum estrogen and progesterone levels in 90 premenopausal women from Iran. The cross-sectional study also identified positive associations for combined chemical exposures, although the authors cautioned that the mixture findings are exploratory and cannot establish causality.

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

24

Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

Understanding opioid risks can help prevent accidental overdoses

24

Aug 2026

Understanding opioid risks can help prevent accidental overdoses

According to numbers calculated from the CDC, approximately 80,000 people died last year from a drug overdose, which represents about 21 deaths per 100,000 residents in the U.S. alone. Overdose deaths are preventable, and in most of the cases we see, they are completely accidental.

Tick-borne alpha-gal syndrome poses potential risks during blood transfusions

24

Aug 2026

Tick-borne alpha-gal syndrome poses potential risks during blood transfusions

A new multi-institute study led by researchers at Dartmouth Health and Geisel School of Medicine at Dartmouth suggests that alpha-gal syndrome, the tick-borne disease that can result in a chronic allergy to meat and animal byproducts, also may complicate certain patients' ability to safely receive a blood plasma or platelet transfusion.

An 11-year study found the same social media pattern again and again

24

Aug 2026

An 11-year study found the same social media pattern again and again

Across 11 annual U.S. surveys involving about 183,000 adults, higher social media use was consistently associated with self-reported depression, with social media ranking among the strongest predictors in machine-learning models. SHAP analyses suggested that social media use became a stronger positive signal for depression at around 150 minutes per day, although the authors stress that this is not an established clinical threshold and requires longitudinal and experimental testing.

Japan vaccinated heavily during COVID-19. Why are so many unsure about vaccinating next time?

24

Aug 2026

Japan vaccinated heavily during COVID-19. Why are so many unsure about vaccinating next time?

A nationwide Japanese survey found that only 53.1% of respondents said they would accept vaccination in a hypothetical future pandemic with COVID-19-like fatality, despite substantially higher previous COVID-19 vaccine uptake. Willingness varied by demographics, perceived disease risk, exposure to misinformation, vaccine characteristics, and practical factors such as cost, evidence, professional recommendations, and accessibility.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.